Contrastingly, in clinical trials, GLP-1 agonists lower weight less dramatically. Regardless, their use could be beneficial as obesity increases surgical morbidity and operative costs (time) in those undergoing benign hysterectomy with BMI over 40 kg/m2 [2]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.